logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-GU 2019—Avelumab+axitinib bests sunitinib in previously untreated clear-cell aRCC

Results from the ongoing JAVELIN Renal 101 phase 3 trial.